Talphera (TLPH) Net Margin (2011 - 2025)

Talphera (TLPH) posted quarterly Net Margin of 270.37% for Q1 2025, up 116.86% quarter-over-quarter from 1603.2% in Q4 2023.

Talphera (TLPH) Net Margin (2011 - 2025) Analysis & Trends

Talphera's Net Margin history runs 14 years deep, the most recent figure standing at 270.37% for Q1 2025.

In Q1 2025, Net Margin changed N/A year-over-year to 270.37%; the TTM figure through Dec 2025 stood at 260.71% (changed N/A YoY), while the FY2025 annual figure was 260.71%, changed N/A from the prior year.
Net Margin for Q1 2025 stood at 270.37%, up from 1603.2% in the prior quarter.
The five-year high for Net Margin was 1639.92% in Q1 2023, with the low at 395850.0% in Q4 2021.
The 4-year median for Net Margin is 1407.58% (2023), against an average of 40402.29%.
The sharpest annual moves came in 2021 and 2023: Net Margin tumbled 39464160 bps in 2021, then surged 255825 bps in 2023.
Talphera's Net Margin stood at 395850.0% in 2021, then soared by 100 bps to 918.33% in 2022, then sank by 75 bps to 1603.2% in 2023, then surged by 117 bps to 270.37% in 2025.
Business Quant data shows TLPH's Net Margin at 270.37% in Q1 2025, 1603.2% in Q4 2023, and 1211.97% in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	-
2	Teva Pharmaceutical Industries	42.85 Bn	39.19 Bn	2.15 Bn	-13.91%
3	Zoetis	31.40 Bn	29.73 Bn	1.05 Bn	35.09%
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	9.28%
5	United Therapeutics	22.16 Bn	19.49 Bn	683.80 Mn	42.51%
6	Viatris	18.71 Bn	17.83 Bn	1.46 Bn	-3.16%
7	Neurocrine Biosciences	15.42 Bn	15.03 Bn	935.80 Mn	15.06%
8	Elanco Animal Health	11.70 Bn	11.17 Bn	798.00 Mn	3.95%
9	Dr Reddys Laboratories	10.09 Bn	9.93 Bn	-	-
10	Talphera	89.88 Mn	89.88 Mn	-	-

Download Data